Kymera’s KT-621 STAT6 degrader receives FDA Fast Track designation for eosinophilic asthma

Kymera Therapeutics, Inc. (Nasdaq: KYMR), a clinical-stage biotech headquartered in Watertown, Massachusetts, announced that US FDA has granted Fast Track Designation to KT-621, an oral small-molecule degrader of signal transducer and activator of transcription 6 (STAT6), for moderate to severe eosinophilic asthma. The designation is the second Fast Track award for KT-621; the first covered moderate to severe atopic dermatitis (AD).

Fast Track designation gives Kymera more frequent interactions with FDA during development and creates eligibility for accelerated approval and priority review if applicable criteria are subsequently met.

The clinical case supporting the asthma designation rests on data generated in a population not primarily enrolled for asthma. In the BroADen Phase Ib trial in AD patients, a subset with comorbid asthma showed a median 56% reduction in fractional exhaled nitric oxide (FeNO), a biomarker of pulmonary Type 2 inflammation, and improvements on the Asthma Control Questionnaire-5 (ACQ-5). Earlier Phase I data in AD patients reported median STAT6 degradation of 94% in skin and 98% in blood across the 100 mg and 200 mg dose cohorts.

The dedicated asthma program is the BREADTH Phase IIb trial (NCT07323654), a randomized, double-blind, placebo-controlled, dose-ranging study enrolling adults with moderate to severe eosinophilic asthma. Entry criteria include blood eosinophils of at least 300 cells/µL and FeNO of at least 25 ppb. The primary endpoint is change from baseline in forced expiratory volume in one second (FEV1). Data are expected in late 2027. A parallel Phase IIb study, BROADEN2, is evaluating KT-621 in moderate to severe AD, with results expected by mid-2027. Both studies are designed to support dose selection for subsequent Phase III registration trials across Type 2 inflammatory diseases.

KT-621 degrades STAT6, the transcription factor that mediates IL-4 and IL-13 signaling and drives Type 2 inflammation. Preclinical publications in the Annals of Allergy, Asthma & Immunology and the American Journal of Respiratory and Critical Care Medicine have described potent and selective STAT6 degradation inhibiting IL-4/IL-13 in mouse asthma models and blocking TH2 inflammation in a house dust mite model. KT-621 has no prior regulatory approval from the US FDA, EMA, or NMPA.

Research context

The approved biologic landscape in eosinophilic asthma targets upstream cytokines or their receptors rather than the intracellular transcription factor they activate. Mepolizumab, reslizumab, and benralizumab block the IL-5 axis; dupilumab targets the shared IL-4Rα subunit used by both IL-4 and IL-13; tezepelumab blocks thymic stromal lymphopoietin upstream of the Type 2 cascade. All are administered by injection. Oral options in asthma remain limited to leukotriene modifiers and, in some markets, low-dose theophylline — neither of which targets the IL-4/IL-13 axis directly.

KT-621’s mechanism positions it downstream of the cytokines themselves, degrading STAT6 rather than neutralizing the ligands or blocking receptor binding. Unlike dupilumab, which prevents IL-4Rα engagement, KT-621 eliminates the transcription factor that both IL-4 and IL-13 depend on for nuclear signalling. Whether systemic STAT6 degradation produces a differentiated efficacy or safety profile relative to receptor-level blockade remains to be established in randomized trials. The BREADTH study’s FEV1 primary endpoint and its eosinophil and FeNO entry criteria will allow some comparison with the pivotal datasets that supported approved biologics, though cross-trial comparisons carry the usual confounds.